Latest news with #Mesothelioma
Yomiuri Shimbun
25-05-2025
- Health
- Yomiuri Shimbun
Asbestos in Noto's Damaged Buildings Causes Health Concerns; Volunteering Suspended, Other Measures Requested
The Yomiuri Shimbun Members of a survey team inspect a damaged building in Nanao, Ishikawa Prefecture, on May 6. WAJIMA/SUZU, Ishikawa — Exposed asbestos was found in several damaged buildings in the Noto region of Ishikawa Prefecture, which was hit severely by the Noto Peninsula Earthquake and torrential rains last year, and restrictions have been placed on volunteering and other activities amid health concerns. Asbestos, a fibrous mineral that could cause mesothelioma and lung cancer if inhaled, was found in the ceiling and beams of Hotel Kairakuso, a Japanese style inn in Suzu, in mid-April. The inn closed after heavy rainfall in September last year caused soil and sand to surge inside. Five or six pieces of asbestos with diameters of 3 to 10 centimeters were found broken and determined to be the highly toxic blue asbestos variety. The Ishikawa prefectural government has asked the owner of the inn to stop accepting volunteers and to take measures to keep the asbestos contained. A notice saying 'No entry except by authorized personnel' was posted at the entrance of the inn, and wood was used to block people from entering. Courtesy of the Mesothelioma, Pneumoconiosis, and Asbestos Center Asbestos sprayed on steel frames is seen in Suzu, Ishikawa Prefecture, in April The central government and experts are continuing to investigate the situation and raising awareness. From February to March last year, the Environment Ministry conducted an asbestos survey on disaster-hit buildings in six municipalities. Exposed asbestos was found in 12 of the 64 buildings surveyed, and owners were instructed to take measures to prevent the fibrous mineral from being dispersed. A team also surveyed buildings in Nanao and Wajima in the prefecture on May 6. The team was led by Fuyushi Nagakura, secretary general of the Tokyo-based non-profit organization Mesothelioma, Pneumoconiosis, and Asbestos Center, and Shigeharu Nakachi, professor of environmental chemistry at Kumamoto Gakuen University. In Nanao, exposed asbestos was found in a building scheduled to be demolished with public funds. The team asked the prefectural government to take such measures as covering the building with blue sheets. As of the end of April, about 26,000 buildings in the prefecture had been demolished with public funds, according to the prefectural government. Another 14,000 buildings are scheduled to be demolished in the same way by October. The prefectural government is calling on demolition contractors to wear dust masks and take other measures.
Globe and Mail
06-03-2025
- Business
- Globe and Mail
Mesothelioma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, 'Mesothelioma Pipeline Insight 2025' report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Mesothelioma pipeline landscape. It covers the Mesothelioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Mesothelioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Mesothelioma Pipeline Outlook Report Key Takeaways from the Mesothelioma Pipeline Report In March 2025, Genmab initiated a Phase 1/2 study of Rina-S (GEN1184), a folate receptor alpha (FRα)-targeted antibody-drug conjugate, to evaluate its safety, tolerability, pharmacokinetics (PK), and antitumor activity in participants with selected locally advanced and/or metastatic solid tumors, including epithelial ovarian cancer, endometrial cancer, breast cancer, non-small cell lung cancer, and mesothelioma. DelveInsight's Mesothelioma pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Mesothelioma treatment. The leading Mesothelioma Companies such as Polaris Pharmaceuticals, AstraZeneca, MedImmune LLC, Takeda, RS Oncology LLC, Vivace Therapeutics, Inc., VM Oncology, LLC, KaliVir Immunotherapeutics, UTC Therapeutics Inc., Tango Therapeutics, Inc., Verismo Therapeutics, SpringWorks Therapeutics, Inc., Gilead Sciences, Nurix Therapeutics, Inc., Amphera BV, Merck Sharp & Dohme LLC, Constellation Pharmaceuticals, BridGene Biosciences Inc., Aromics Therapeutics, and Ascentage Pharma Group Inc. and others. Promising Mesothelioma Therapies such as Pembrolizumab, Lenvatinib, Nivolumab, Ipilimumab, ZD1839, Zometa, Durvalumab, and others. Learn how leading Mesothelioma Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!" @ Mesothelioma Clinical Trials Assessment Mesothelioma Emerging Drugs Pegargiminase: Polaris Pharmaceuticals Pegargiminase (ADI‑PEG 20), is a biologic in late-stage clinical development for a wide range of cancers. It is a novel therapeutic protein being developed for cancers with a unique metabolic trait. Pegargiminase deprives the cancer cells of the amino acid Arginine by converting plasma-borne arginine into citrulline. At the core of their deficiency is a down-regulation of Argininosuccinate Synthase (ASS1), an enzyme needed to synthesize arginine. To survive, the cancer cells must 'rewire' their metabolism. This exerts a stress on the cells that renders them more susceptible to conventional chemotherapies. Pegargiminase has also gained Orphan Drug Designation for mesothelioma both in the U.S. and in Europe. Currently, the drug is in Preregistration stage of its development for the treatment of Mesothelioma. Volrustomig: AstraZeneca Volrustomig is an engineered Fragment Crystallizable (Fc) domain bispecific human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, volrustomig targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Mesothelioma. Tremelimumab: MedImmune LLC Tremelimumab is a type of monoclonal antibody and a type of immune checkpoint inhibitor. It is a drug that binds to the protein CTLA-4 to help immune cells kill cancer cells better and is used to treat different types of cancer. Tremelimumab is directed against cytotoxic T- lymphocyte-associated protein 4 (CTLA-4). By blocking the activity of CTLA-4, tremelimumab 'releases the brakes' on T cell activation and boosts the immune response against cancer cells. It is a fully human monoclonal antibody, which stimulates the immune system to destroy cancer cells through binding to the protein CTLA-4, expressed on the surface of activated T-lymphocytes. Tremelimumab has been granted Orphan Drug Designation and Fast Track Designation form the US Food and Drug Administration. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Mesothelioma. TAK-500: Takeda TAK-500 is a first-in-class STING agonist immunostimulatory antibody drug conjugate (iADC) that delivers dazostinag to CCR2+ myeloid cells in the tumor microenvironment. By targeting the STING pathway and CCR2 expressing myeloid cells, TAK-500 may offer enhanced potency via improved PK and selective delivery. TAK-500 has three possible mechanisms of action: activation of IFN response, reprogramming of suppressive intratumoral CCR2+ myeloid cells, and blockade of suppressive tumor-associated macrophage recruitment. Activation of STING leads to the production of proinflammatory cytokines that activate dendritic cells, macrophages, and natural killer cells, and subsequently mobilize adaptive immune cells against tumor cells. Combining TAK-500 with radiation and/or checkpoint inhibitors led to enhanced antitumor activity in preclinical studies. Dying tumor cells release tumor antigens and tumor-derived cGAMP, which continue to activate the STING pathway. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Mesothelioma. RSO-021: RS Oncology LLC RSO-021 is a naturally occurring, sulfur-rich, cyclic oligopeptide of the thiopeptide class, which covalently inactivates PRX3, leading to catastrophic oxidative stress and cell death. It is a novel first-in-class small molecule that irreversibly binds and inhibits mitochondrial peroxiredoxin 3 (PRX3). Inhibition of the PRX3 antioxidant signaling network in mitochondria results in selective killing of malignant cells by upregulation of oxidative stress; in contrast, healthy tissue is spared. In pre-clinical models RSO-021 reduces tumor growth in mice, sensitizes tumor cells to apoptosis and reduces the expression of pro-metastatic epithelial to mesenchymal (EMT) genes. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Mesothelioma. The Mesothelioma Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Mesothelioma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mesothelioma Treatment. Mesothelioma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Mesothelioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mesothelioma market. From early-stage research to late-phase Mesothelioma Clinical Trials, our analysis covers key Mesothelioma Companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don't miss this opportunity to stay informed—download now! @ Mesothelioma Treatment Drugs Mesothelioma Companies Polaris Pharmaceuticals, AstraZeneca, MedImmune LLC, Takeda, RS Oncology LLC, Vivace Therapeutics, Inc., VM Oncology, LLC, KaliVir Immunotherapeutics, UTC Therapeutics Inc., Tango Therapeutics, Inc., Verismo Therapeutics, SpringWorks Therapeutics, Inc., Gilead Sciences, Nurix Therapeutics, Inc., Amphera BV, Merck Sharp & Dohme LLC, Constellation Pharmaceuticals, BridGene Biosciences Inc., Aromics Therapeutics, and Ascentage Pharma Group Inc. and others. Stay updated with the latest Mesothelioma Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Mesothelioma Market Drivers and Barriers, and Future Perspectives Scope of the Mesothelioma Pipeline Report Coverage- Global Mesothelioma Companies- Polaris Pharmaceuticals, AstraZeneca, MedImmune LLC, Takeda, RS Oncology LLC, Vivace Therapeutics, Inc., VM Oncology, LLC, KaliVir Immunotherapeutics, UTC Therapeutics Inc., Tango Therapeutics, Inc., Verismo Therapeutics, SpringWorks Therapeutics, Inc., Gilead Sciences, Nurix Therapeutics, Inc., Amphera BV, Merck Sharp & Dohme LLC, Constellation Pharmaceuticals, BridGene Biosciences Inc., Aromics Therapeutics, and Ascentage Pharma Group Inc. and others Mesothelioma Therapies- Pembrolizumab, Lenvatinib, Nivolumab, Ipilimumab, ZD1839, Zometa, Durvalumab, and others. Mesothelioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Mesothelioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Find answers in our latest Mesothelioma Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!" @ Mesothelioma Emerging Drugs and Companies Table of Content Introduction Executive Summary Mesothelioma: Overview Pipeline Therapeutics Therapeutic Assessment Mesothelioma – DelveInsight's Analytical Perspective Late Stage Products (Preregistration) Pegargiminase: Polaris Pharmaceuticals Drug profiles in the detailed report….. Mid Stage Products (Phase II) Tremelimumab: MedImmune LLC Drug profiles in the detailed report….. Early Stage Products (Phase I/II) TAK-500: Takeda Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Mesothelioma Key Companies Mesothelioma Key Products Mesothelioma- Unmet Needs Mesothelioma- Market Drivers and Barriers Mesothelioma- Future Perspectives and Conclusion Mesothelioma Analyst Views Mesothelioma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
